oYo-Link® VcMMAE Antibody Labeling Kit - Labels 500ug Reference: AT7001-500 Research Use Only Application: Antibody conjugation Kit for Targeted cell death; Targeted cell death for cancer cells; High-throughput screening with cell killing assays oYo-Link® VcMMAE is an Antibody-Drug Conjugation Kit allowing for site-specific labeling of Monomethyl Auristatin E labels to the heavy-chains of oYo-Link®-compatible antibodies with up to two labels per antibody. VcMMAE is an anti-mitotic agent linked via the lysosomally cleavable dipeptide, valine-citrulline (vc). oYo-Link® limits the attachment of the VcMMAE drugs to the heavy chains of the antibody and therefore ensures that the drug label does not interfere with antibody binding. Furthermore, site-specific labeling limits 1-2 VcMMAE drugs to be attached per antibody, providing precise antibody-drug conjugate ratios. The antibody labeling procedure simply requires mixing oYo-Link® VcMMAE with the desired antibody followed by photocrosslinking with non-damaging black light (365 nm). Photocrosslinking can be carried in most buffers, including those containing amine-containing molecules (e.g. TRIS, glycine) or storage proteins (see Buffer Compatibility Table). Catalog # AT7001. Requirements: To label your compatible antibodies with oYo-Link®, you will need a Light Source emitting at 365nm (6-10W). Use your own Compatible Device from our list or purchase AlphaThera's LED Photo-Crosslinking Device. Technical Support: For science questions or questions concerning compatibility email support@alphathera.com
oYo-Link® VcMMAE Antibody Labeling Kit - Labels 1mg Reference: AT7001-1000 Research Use Only Application: Antibody conjugation Kit for Targeted cell death; Targeted cell death for cancer cells; High-throughput screening with cell killing assays oYo-Link® VcMMAE is an Antibody-Drug Conjugation Kit allowing for site-specific labeling of Monomethyl Auristatin E labels to the heavy-chains of oYo-Link®-compatible antibodies with up to two labels per antibody. VcMMAE is an anti-mitotic agent linked via the lysosomally cleavable dipeptide, valine-citrulline (vc). oYo-Link® limits the attachment of the VcMMAE drugs to the heavy chains of the antibody and therefore ensures that the drug label does not interfere with antibody binding. Furthermore, site-specific labeling limits 1-2 VcMMAE drugs to be attached per antibody, providing precise antibody-drug conjugate ratios. The antibody labeling procedure simply requires mixing oYo-Link® VcMMAE with the desired antibody followed by photocrosslinking with non-damaging black light (365 nm). Photocrosslinking can be carried in most buffers, including those containing amine-containing molecules (e.g. TRIS, glycine) or storage proteins (see Buffer Compatibility Table). Catalog # AT7001. Requirements: To label your compatible antibodies with oYo-Link®, you will need a Light Source emitting at 365nm (6-10W). Use your own Compatible Device from our list or purchase AlphaThera's LED Photo-Crosslinking Device. Technical Support: For science questions or questions concerning compatibility email support@alphathera.com
oYo-Link® VcMMAE Antibody Labeling Kit - Labels 100ug mIgG1 Ab Reference: AT7001-mIgG1-100 Research Use Only Application: Antibody conjugation Kit for Targeted cell death; Targeted cell death for cancer cells; High-throughput screening with cell killing assays oYo-Link® VcMMAE is an Antibody-Drug Conjugation Kit allowing for site-specific labeling of Monomethyl Auristatin E labels to the heavy-chains of oYo-Link®-compatible antibodies with up to two labels per antibody. VcMMAE is an anti-mitotic agent linked via the lysosomally cleavable dipeptide, valine-citrulline (vc). oYo-Link® limits the attachment of the VcMMAE drugs to the heavy chains of the antibody and therefore ensures that the drug label does not interfere with antibody binding. Furthermore, site-specific labeling limits 1-2 VcMMAE drugs to be attached per antibody, providing precise antibody-drug conjugate ratios. The antibody labeling procedure simply requires mixing oYo-Link® VcMMAE with the desired antibody followed by photocrosslinking with non-damaging black light (365 nm). Photocrosslinking can be carried in most buffers, including those containing amine-containing molecules (e.g. TRIS, glycine) or storage proteins (see Buffer Compatibility Table). Catalog # AT7001. Requirements: To label your compatible antibodies with oYo-Link®, you will need a Light Source emitting at 365nm (6-10W). Use your own Compatible Device from our list or purchase AlphaThera's LED Photo-Crosslinking Device. Technical Support: For science questions or questions concerning compatibility email support@alphathera.com
oYo-Link® VcMMAE Antibody Labeling Kit - Labels 500ug mIgG1 Ab Reference: AT7001-mIgG1-500 Research Use Only Application: Antibody conjugation Kit for Targeted cell death; Targeted cell death for cancer cells; High-throughput screening with cell killing assays oYo-Link® VcMMAE is an Antibody-Drug Conjugation Kit allowing for site-specific labeling of Monomethyl Auristatin E labels to the heavy-chains of oYo-Link®-compatible antibodies with up to two labels per antibody. VcMMAE is an anti-mitotic agent linked via the lysosomally cleavable dipeptide, valine-citrulline (vc). oYo-Link® limits the attachment of the VcMMAE drugs to the heavy chains of the antibody and therefore ensures that the drug label does not interfere with antibody binding. Furthermore, site-specific labeling limits 1-2 VcMMAE drugs to be attached per antibody, providing precise antibody-drug conjugate ratios. The antibody labeling procedure simply requires mixing oYo-Link® VcMMAE with the desired antibody followed by photocrosslinking with non-damaging black light (365 nm). Photocrosslinking can be carried in most buffers, including those containing amine-containing molecules (e.g. TRIS, glycine) or storage proteins (see Buffer Compatibility Table). Catalog # AT7001. Requirements: To label your compatible antibodies with oYo-Link®, you will need a Light Source emitting at 365nm (6-10W). Use your own Compatible Device from our list or purchase AlphaThera's LED Photo-Crosslinking Device. Technical Support: For science questions or questions concerning compatibility email support@alphathera.com
oYo-Link® DM1 Antibody Labeling Kit - Labels 100ug Reference: AT7002-100 Research Use Only Application: Antibody conjugation Kit for Targeted cell death; Targeted cell death for cancer cells; High-throughput screening with cell killing assays oYo-Link® DM1 is an Antibody-Drug Conjugation Kit allowing for site-specific labeling of DM1 drug labels to the heavy-chains of compatible antibodies with up to two labels per antibody. oYo-Link® limits the attachment of the DBCO drugs to the heavy chains of the antibody and therefore ensures that the drug label does not interfere with antibody binding. Furthermore, site-specific labeling limits 1-2 DBCO drugs to be attached per antibody, providing precise antibody-drug conjugate ratios. As a synthetic derivative of the microtubule-targeted agent mertansine, also known as the maytansinoid DM1, the DM1 ADC is an antibody-conjugatable, anti-mitotic agent that overcomes systemic toxicity associated with mertansine and enhances tumor-specific delivery. The antibody labeling procedure simply requires mixing oYo-Link® DM1 with the desired antibody followed by photocrosslinking with non-damaging black light (365 nm). Photocrosslinking can be carried in most buffers, including those containing amine-containing molecules (e.g. TRIS, glycine) or storage proteins (see Buffer Compatibility Table). Catalog # AT7002. Requirements: To label your compatible antibodies with oYo-Link®, you will need a Light Source emitting at 365nm (6-10W). Use your own Compatible Device from our list or purchase AlphaThera's LED Photo-Crosslinking Device. Technical Support: For science questions or questions concerning compatibility email support@alphathera.com
oYo-Link® DM1 Antibody Labeling Kit- Labels 500ug Reference: AT7002-500 Research Use Only Application: Antibody conjugation Kit for Targeted cell death; Targeted cell death for cancer cells; High-throughput screening with cell killing assays oYo-Link® DM1 is an Antibody-Drug Conjugation Kit allowing for site-specific labeling of DM1 drug labels to the heavy-chains of compatible antibodies with up to two labels per antibody. oYo-Link® limits the attachment of the DBCO drugs to the heavy chains of the antibody and therefore ensures that the drug label does not interfere with antibody binding. Furthermore, site-specific labeling limits 1-2 DBCO drugs to be attached per antibody, providing precise antibody-drug conjugate ratios. As a synthetic derivative of the microtubule-targeted agent mertansine, also known as the maytansinoid DM1, the DM1 ADC is an antibody-conjugatable, anti-mitotic agent that overcomes systemic toxicity associated with mertansine and enhances tumor-specific delivery. The antibody labeling procedure simply requires mixing oYo-Link® DM1 with the desired antibody followed by photocrosslinking with non-damaging black light (365 nm). Photocrosslinking can be carried in most buffers, including those containing amine-containing molecules (e.g. TRIS, glycine) or storage proteins (see Buffer Compatibility Table). Catalog # AT7002. Requirements: To label your compatible antibodies with oYo-Link®, you will need a Light Source emitting at 365nm (6-10W). Use your own Compatible Device from our list or purchase AlphaThera's LED Photo-Crosslinking Device. Technical Support: For science questions or questions concerning compatibility email support@alphathera.com
oYo-Link® DM1 Antibody Labeling Kit - Labels 1mg Reference: AT7002-1000 Research Use Only Application: Antibody conjugation Kit for Targeted cell death; Targeted cell death for cancer cells; High-throughput screening with cell killing assays oYo-Link® DM1 is an Antibody-Drug Conjugation Kit allowing for site-specific labeling of DM1 drug labels to the heavy-chains of compatible antibodies with up to two labels per antibody. oYo-Link® limits the attachment of the DBCO drugs to the heavy chains of the antibody and therefore ensures that the drug label does not interfere with antibody binding. Furthermore, site-specific labeling limits 1-2 DBCO drugs to be attached per antibody, providing precise antibody-drug conjugate ratios. As a synthetic derivative of the microtubule-targeted agent mertansine, also known as the maytansinoid DM1, the DM1 ADC is an antibody-conjugatable, anti-mitotic agent that overcomes systemic toxicity associated with mertansine and enhances tumor-specific delivery. The antibody labeling procedure simply requires mixing oYo-Link® DM1 with the desired antibody followed by photocrosslinking with non-damaging black light (365 nm). Photocrosslinking can be carried in most buffers, including those containing amine-containing molecules (e.g. TRIS, glycine) or storage proteins (see Buffer Compatibility Table). Catalog # AT7002. Requirements: To label your compatible antibodies with oYo-Link®, you will need a Light Source emitting at 365nm (6-10W). Use your own Compatible Device from our list or purchase AlphaThera's LED Photo-Crosslinking Device. Technical Support: For science questions or questions concerning compatibility email support@alphathera.com
oYo-Link® DM1 Antibody Labeling Kit- Labels 100ug mIgG1 Ab Reference: AT7002-mIgG1-100 Research Use Only Application: Antibody conjugation Kit for Targeted cell death; Targeted cell death for cancer cells; High-throughput screening with cell killing assays oYo-Link® DM1 is an Antibody-Drug Conjugation Kit allowing for site-specific labeling of DM1 drug labels to the heavy-chains of compatible antibodies with up to two labels per antibody. oYo-Link® limits the attachment of the DBCO drugs to the heavy chains of the antibody and therefore ensures that the drug label does not interfere with antibody binding. Furthermore, site-specific labeling limits 1-2 DBCO drugs to be attached per antibody, providing precise antibody-drug conjugate ratios. As a synthetic derivative of the microtubule-targeted agent mertansine, also known as the maytansinoid DM1, the DM1 ADC is an antibody-conjugatable, anti-mitotic agent that overcomes systemic toxicity associated with mertansine and enhances tumor-specific delivery. The antibody labeling procedure simply requires mixing oYo-Link® DM1 with the desired antibody followed by photocrosslinking with non-damaging black light (365 nm). Photocrosslinking can be carried in most buffers, including those containing amine-containing molecules (e.g. TRIS, glycine) or storage proteins (see Buffer Compatibility Table). Catalog # AT7002. Requirements: To label your compatible antibodies with oYo-Link®, you will need a Light Source emitting at 365nm (6-10W). Use your own Compatible Device from our list or purchase AlphaThera's LED Photo-Crosslinking Device. Technical Support: For science questions or questions concerning compatibility email support@alphathera.com
oYo-Link® DM1 Antibody Labeling Kit - Labels 500ug mIgG1 Ab Reference: AT7002-mIgG1-500 Research Use Only Application: Antibody conjugation Kit for Targeted cell death; Targeted cell death for cancer cells; High-throughput screening with cell killing assays oYo-Link® DM1 is an Antibody-Drug Conjugation Kit allowing for site-specific labeling of DM1 drug labels to the heavy-chains of compatible antibodies with up to two labels per antibody. oYo-Link® limits the attachment of the DBCO drugs to the heavy chains of the antibody and therefore ensures that the drug label does not interfere with antibody binding. Furthermore, site-specific labeling limits 1-2 DBCO drugs to be attached per antibody, providing precise antibody-drug conjugate ratios. As a synthetic derivative of the microtubule-targeted agent mertansine, also known as the maytansinoid DM1, the DM1 ADC is an antibody-conjugatable, anti-mitotic agent that overcomes systemic toxicity associated with mertansine and enhances tumor-specific delivery. The antibody labeling procedure simply requires mixing oYo-Link® DM1 with the desired antibody followed by photocrosslinking with non-damaging black light (365 nm). Photocrosslinking can be carried in most buffers, including those containing amine-containing molecules (e.g. TRIS, glycine) or storage proteins (see Buffer Compatibility Table). Catalog # AT7002. Requirements: To label your compatible antibodies with oYo-Link®, you will need a Light Source emitting at 365nm (6-10W). Use your own Compatible Device from our list or purchase AlphaThera's LED Photo-Crosslinking Device. Technical Support: For science questions or questions concerning compatibility email support@alphathera.com
oYo-Link® VcMMAF Antibody Labeling Kit - Labels 100ug Reference: AT7003-100 Research Use Only Application: Antibody conjugation Kit for Targeted cell death; Targeted cell death for cancer cells; High-throughput screening with cell killing assays oYo-Link® VcMMAF is an Antibody-Drug Conjugation Kit allowing for site-specific labeling of Monomethyl Auristatin F. labels to the heavy-chains of oYo-Link®-compatible antibodies with up to two labels per antibody. VcMMAF is an anti-mitotic agent linked via the lysosomally cleavable dipeptide, valine-citrulline (vc). oYo-Link® limits the attachment of the VcMMAF drugs to the heavy chains of the antibody and therefore ensures that the drug label does not interfere with antibody binding. Furthermore, site-specific labeling limits 1-2 VcMMAF drugs to be attached per antibody, providing precise antibody-drug conjugate ratios. The antibody labeling procedure simply requires mixing oYo-Link® VcMMAF with the desired antibody followed by photocrosslinking with non-damaging black light (365 nm). Photocrosslinking can be carried in most buffers, including those containing amine-containing molecules (e.g. TRIS, glycine) or storage proteins (see Buffer Compatibility Table). Catalog # AT7003. Requirements: To label your compatible antibodies with oYo-Link®, you will need a Light Source emitting at 365nm (6-10W). Use your own Compatible Device from our list or purchase AlphaThera's LED Photo-Crosslinking Device. Technical Support: For science questions or questions concerning compatibility email support@alphathera.com
oYo-Link® VcMMAF Antibody Labeling Kit - Labels 500ug Reference: AT7003-500 Research Use Only Application: Antibody conjugation Kit for Targeted cell death; Targeted cell death for cancer cells; High-throughput screening with cell killing assays oYo-Link® VcMMAF is an Antibody-Drug Conjugation Kit allowing for site-specific labeling of Monomethyl Auristatin F. labels to the heavy-chains of oYo-Link®-compatible antibodies with up to two labels per antibody. VcMMAF is an anti-mitotic agent linked via the lysosomally cleavable dipeptide, valine-citrulline (vc). oYo-Link® limits the attachment of the VcMMAF drugs to the heavy chains of the antibody and therefore ensures that the drug label does not interfere with antibody binding. Furthermore, site-specific labeling limits 1-2 VcMMAF drugs to be attached per antibody, providing precise antibody-drug conjugate ratios. The antibody labeling procedure simply requires mixing oYo-Link® VcMMAF with the desired antibody followed by photocrosslinking with non-damaging black light (365 nm). Photocrosslinking can be carried in most buffers, including those containing amine-containing molecules (e.g. TRIS, glycine) or storage proteins (see Buffer Compatibility Table). Catalog # AT7003. Requirements: To label your compatible antibodies with oYo-Link®, you will need a Light Source emitting at 365nm (6-10W). Use your own Compatible Device from our list or purchase AlphaThera's LED Photo-Crosslinking Device. Technical Support: For science questions or questions concerning compatibility email support@alphathera.com
oYo-Link® VcMMAF Antibody Labeling Kit- Labels 1mg Reference: AT7003-1000 Research Use Only Application: Antibody conjugation Kit for Targeted cell death; Targeted cell death for cancer cells; High-throughput screening with cell killing assays oYo-Link® VcMMAF is an Antibody-Drug Conjugation Kit allowing for site-specific labeling of Monomethyl Auristatin F. labels to the heavy-chains of oYo-Link®-compatible antibodies with up to two labels per antibody. VcMMAF is an anti-mitotic agent linked via the lysosomally cleavable dipeptide, valine-citrulline (vc). oYo-Link® limits the attachment of the VcMMAF drugs to the heavy chains of the antibody and therefore ensures that the drug label does not interfere with antibody binding. Furthermore, site-specific labeling limits 1-2 VcMMAF drugs to be attached per antibody, providing precise antibody-drug conjugate ratios. The antibody labeling procedure simply requires mixing oYo-Link® VcMMAF with the desired antibody followed by photocrosslinking with non-damaging black light (365 nm). Photocrosslinking can be carried in most buffers, including those containing amine-containing molecules (e.g. TRIS, glycine) or storage proteins (see Buffer Compatibility Table). Catalog # AT7003. Requirements: To label your compatible antibodies with oYo-Link®, you will need a Light Source emitting at 365nm (6-10W). Use your own Compatible Device from our list or purchase AlphaThera's LED Photo-Crosslinking Device. Technical Support: For science questions or questions concerning compatibility email support@alphathera.com